Krystal Biotech, Inc. (KRYS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Krystal Biotech, Inc. (KRYS) closed at USD 330.69 on 2026-10-14, a change of +74.4 % over the past year, with a market capitalization of USD 9.77B.

Krystal Biotech, Inc. recent closing prices

DateClose (USD)
2026-10-14330.69
2026-10-13321.16
2026-10-12332.07
2026-10-09331.61
2026-10-08327.30
2026-10-07324.57
2026-10-06326.81

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Krystal Biotech, Inc. key figures

Previous close
USD 330.69 (2026-10-14)
1-year change
+74.4 %
Market cap
USD 9.77B
Enterprise value
USD 8.93B
P/E ratio (trailing)
40.24
P/E ratio (forward)
36.65
EPS (trailing)
8.20
EPS (forward)
9.00
PEG ratio
n/a
Price to book
7.19
Revenue growth
24.1 %
Earnings growth
38.8 %
Dividend per share (trailing)
0.00
Short ratio
12.53
Employees
295
Analyst consensus (third-party)
strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Krystal Biotech, Inc. and compare it with other stocks.

Analyze KRYSAll Other US Stocks stocks

Stock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Krystal Biotech, Inc. shares.